Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Prepaid Assets (2016 - 2025)

Ani Pharmaceuticals (ANIP) has disclosed Prepaid Assets for 16 consecutive years, with $23.2 million as the latest value for Q4 2025.

  • Quarterly Prepaid Assets rose 29.01% to $23.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $23.2 million through Dec 2025, up 29.01% year-over-year, with the annual reading at $23.2 million for FY2025, 29.01% up from the prior year.
  • Prepaid Assets hit $23.2 million in Q4 2025 for Ani Pharmaceuticals, up from $18.6 million in the prior quarter.
  • In the past five years, Prepaid Assets ranged from a high of $23.3 million in Q1 2025 to a low of $4.7 million in Q3 2021.
  • Historically, Prepaid Assets has averaged $12.0 million across 5 years, with a median of $9.5 million in 2022.
  • Biggest five-year swings in Prepaid Assets: decreased 11.03% in 2023 and later skyrocketed 133.49% in 2024.
  • Year by year, Prepaid Assets stood at $7.6 million in 2021, then grew by 10.52% to $8.4 million in 2022, then soared by 107.46% to $17.4 million in 2023, then rose by 3.3% to $18.0 million in 2024, then rose by 29.01% to $23.2 million in 2025.
  • Business Quant data shows Prepaid Assets for ANIP at $23.2 million in Q4 2025, $18.6 million in Q3 2025, and $15.1 million in Q2 2025.